Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and...
Company Ends Quarter in Strongest Financial Condition Ever VIENNA, Va., Feb. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) reports financial results for the quarter ended...
VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2010 BIO CEO & Investor...
VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the treatment of infectious...
Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion VIENNA, Va., Jan. 13 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM...
Facility Is Also Expected to Generate Revenue Through Contract Manufacturing VIENNA, Va., Jan. 11 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and...
VIENNA, Va., Dec. 1 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of...
VIENNA, Va., Nov. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a...
STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1 HOSPITALIZED PATIENTS VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today...
VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.015 | 0.015 | 0.015 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.015 | 0.015 | 0.015 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.015 | 0.015 | 0.015 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.015 | 0.015 | 0.015 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.015 | 0.015 | 0.015 | 0 | 0 | CS |
| 156 | -0.02 | -57.1428571429 | 0.035 | 0.05 | 0.015 | 6067 | 0.03019218 | CS |
| 260 | -0.185 | -92.5 | 0.2 | 0.2 | 0.015 | 54752 | 0.04319827 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
